VolitionRx Limited (VNRX)

USD 0.61

(2.87%)

Market Cap (In USD)

58.14 Million

Revenue (In USD)

775.3 Thousand

Net Income (In USD)

-35.31 Million

Avg. Volume

130.87 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.43-1.23
PE
-
EPS
-
Beta Value
1.103
ISIN
US9286611077
CUSIP
928661107
CIK
93314
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Cameron Reynolds MBA
Employee Count
-
Website
https://www.volition.com
Ipo Date
2012-03-02
Details
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.